Valuation: MicroPort NeuroScientific Corporation

Capitalization 6.06B 6.86B 878M 740M 675M 644M 1.2B 79.69B 1.24B 7.85B 3.12B 38.36B 3.29B 3.22B 135B P/E ratio 2025 *
22.9x
P/E ratio 2026 * 19.5x
Enterprise value 6.06B 6.86B 878M 740M 675M 644M 1.2B 79.69B 1.24B 7.85B 3.12B 38.36B 3.29B 3.22B 135B EV / Sales 2025 *
7.3x
EV / Sales 2026 * 5.99x
Free-Float
34.75%
Yield 2025 *
1.71%
Yield 2026 * 2.09%
1 day-3.33%
1 week+5.87%
Current month+1.19%
1 month-7.96%
3 months+2.50%
6 months-24.28%
Current year+9.47%
1 week 11.4
Extreme 11.4
12.36
1 month 11.03
Extreme 11.03
13.19
Current year 11.03
Extreme 11.03
14.53
1 year 9.02
Extreme 9.02
19.06
3 years 6.21
Extreme 6.21
19.06
5 years 6.21
Extreme 6.21
26.8
10 years 6.21
Extreme 6.21
26.8
Manager TitleAgeSince
Chief Executive Officer 50 -
Director of Finance/CFO 48 31/05/2018
Chief Administrative Officer 43 06/12/2012
Director TitleAgeSince
Director/Board Member 50 01/11/2020
Director/Board Member 61 01/11/2020
Director/Board Member 45 18/11/2021
Change 5d. change 1-year change 3-years change Capi.($)
-3.33%+5.87%+4.84%-16.24% 908M
+0.05%+2.80%-4.97%+39.07% 140B
-0.34%+4.22%+28.77%+13.74% 15.35B
-1.10%-3.44%-20.66%-67.07% 6.34B
+2.56%-3.35%-28.54%+111.99% 6.28B
-0.79%-4.25%+33.20%+25.79% 2.8B
+0.60%-3.51%-4.14%-22.35% 2.02B
+0.18%-9.91%-67.80%-77.87% 1.71B
-1.27%-1.05%-9.96%-32.17% 1.7B
Average -0.38%-1.09%-7.70%-2.79% 19.69B
Weighted average by Cap. +0.03%+1.60%-3.43%+32.66%

Financials

2025 *2026 *
Net sales 830M 939M 120M 101M 92.46M 88.14M 164M 10.91B 170M 1.07B 427M 5.25B 451M 441M 18.44B 1.01B 1.14B 146M 124M 113M 107M 200M 13.3B 207M 1.31B 521M 6.4B 549M 538M 22.48B
Net income 267M 302M 38.65M 32.61M 29.74M 28.36M 52.68M 3.51B 54.65M 346M 137M 1.69B 145M 142M 5.93B 318M 360M 46.03M 38.83M 35.42M 33.77M 62.74M 4.18B 65.09M 412M 164M 2.01B 173M 169M 7.07B
Net Debt - -
Logo MicroPort NeuroScientific Corporation
MicroPort NeuroScientic Corp is an investment holding company mainly engaged in research, development, and production of neuro-interventional medical devices. The Company's product portfolio covers three major areas of cerebrovascular diseases, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke. The Company provides integrated solutions for patients and doctors with cerebrovascular diseases, including promotion and education regarding the surgical methods and products, recommendations for treatment options, training on surgery and surgical devices, clinical support and postoperative follow-ups. The Company's main products include Tubridge Flow-diverting Stent, Fastrack Microcatheter System, WILLIS Intracranial Stent Graft, and others.
Employees
522
Date Price Change Volume
16/02/26 11.91 $ -3.33% 334,000
13/02/26 12.32 $ +2.16% 3,751,194
12/02/26 12.06 $ +1.43% 1,612,118
11/02/26 11.89 $ -1.16% 3,766,664
10/02/26 12.03 $ +5.43% 5,803,028
Trader
-
Investor
Global
-
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
10.53CNY
Average target price
11.35CNY
Spread / Average Target
+7.84%

Annual profits - Rate of surprise